Citi puts Australia's Telix on positive catalyst watch of Zircaix FDA filing

** Citi opens a 90-day positive catalyst watch on Telix Pharmaceuticals TLX.AX, citing an expected resubmission of kidney cancer imaging agent Zircaix to the US FDA by year-end

** Brokerage says intact FY26 guidance and a good start to the quarter imply modest Q4 growth in Prostate-Specific Membrane Antigen sales for the biopharma firm

** Citi estimates low single-digit net pricing decline as accounts won have greater exposure to more heavily discounted channels

** Brokerage adds TLX's newly launched imaging drug for brain cancer, Pixclara, has an early average selling price of $8,900 per dose, which is higher than expected

** Citi retains TLX's price target of A$31 on ASX-listed shares

** YTD, stock up 14.7%, as of last close